Venus Remedies Secures 10 New Market Authorizations

Venus Remedies is on a roll! We have strengthened our global presence by receiving 10 new Marketing Authorizations across Asia, the Middle East, Europe, Latin America, and Africa. Besides reinforcing our broader international growth strategy, it reflects the company’s sustained focus on expanding access to high-quality injectable therapies in oncology, anti-infectives, critical care, and anticoagulation.

The Key Achievement 

Among the new market authorizations, the most notable achievement is the approval of Midazolam 15 mg in the Philippines. It is a first-time milestone for Venus Remedies in the market. A key drug in the critical care segment, it marks an important breakthrough for the company’s growing regulatory success in Southeast Asia. This signals regulatory trust, portfolio expansion, and reliable therapies to the patients.

"Securing 10 new Market Authorizations is a significant milestone for Venus Remedies, reinforcing the strength of our global portfolio and the confidence international markets place in our products. The first-ever authorization for Midazolam 15 mg/3 ml further elevates this achievement, marking an important addition to our critical care offering and strengthening our presence in key global markets," says Aditi K. Chaudhary, President, International Business, Venus Remedies.

New Approvals Across International Markets

The 10 newly secured MAs cover a diverse mix of product segments and geographical areas. Besides Midazolam 15 mg in the Philippines, these include:

• Methotrexate 1000 mg in Saudi Arabia
• Vancomycin 1 gm in Iraq
• Imipenem & Cilastatin 500 mg in Serbia
• Vincristine and Meropenem 500 mg/1 mg in Chile
• Docetaxel injection USP 80mg in Ethiopia
• Carboplatin Pontus 150mg & 450mg in the Netherlands
• Enoxaparin 20 mg in El Salvador

These key approvals in different critical therapeutic areas and geographical regions reflect a well-balanced international strategy of Venus Remedies. In addition, the approvals have enhanced our reach as a key driver of broader global pharmaceutical access.

Shaping a Healthier Future

Of course, these 10 new MAs represent another meaningful step in Venus Remedies’ journey. But they go beyond regulatory milestones. They represent access to essential quality therapies for patients across multiple regions. By expanding the availability of our drugs, we are addressing urgent treatment needs in diverse healthcare settings. It ensures access to trusted, quality-assured medicines that support better disease management for patients. 

As Venus Remedies continues to grow its global footprint, each new approval brings reinforcement to our portfolio and our vision to attain global health.